Marker Therapeutics Congratulates Helen E. Heslop, MD, DSc (Hon) on Receiving the ASBMT Lifetime Achievement Award
HOUSTON, Feb. 21, 2019 /PRNewswire/ -- Marker Therapeutics, Inc. (Nasdaq:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced that Dr. Helen E. Heslop, Company co-founder and a founding member of Marker's Scientific Advisory Board, has been recognized with the ASBMT Lifetime Achievement Award at the Transplantation & Cellular Therapy Meetings of ASBMT and CIBMTR 2019. The ASBMT Lifetime Achievement Award is presented annually and recognizes an individual who has made continuing contributions to the field of blood and marrow transplantation.
"We would like to congratulate Dr. Heslop on receiving this lifetime achievement award – one of the highest honors in the field – in recognition of her contribution to advancing the science in the field as a leading researcher and innovator in the adoptive T cell and immunotherapy community," commented Peter L. Hoang, President & CEO of Marker Therapeutics. "Over the course of her career, Dr. Heslop's discoveries have led to important advances for patients with a focus on improved outcomes with hematopoietic stem cell transplantation and cancer therapy. We are extremely honored to have Dr. Heslop as an esteemed member of our SAB, where her expertise and guidance have been instrumental in shaping our clinical strategy as we advance our pipeline of novel T cell therapies."
Dr. Heslop, a trained physician-scientist, is Professor of Medicine and Pediatrics and Director of the Center for Cell and Gene Therapy at Baylor College of Medicine, Houston Methodist Hospital and Texas Children's Hospital. In addition, she is the Dan L Duncan Chair and the Associate Director of Clinical Research at the Dan L. Duncan Cancer Center. Dr. Heslop is a key player in translational research focusing on adoptive T cell immunotherapy to improve hematopoietic stem cell transplantation and cancer therapy. She was also a Doris Duke Distinguished Clinical Research Scientist and serves as the current President elect of the American Society for Gene and Cell Therapy (ASGCT) and a past President of the Foundation for Accreditation of Cell Therapy (FACT) and the American Society of Blood and Marrow Transplantation.
About Marker Therapeutics, Inc.
Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Marker's cell therapy technology is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens (i.e. tumor targets) and kill tumor cells expressing those targets. Once infused into patients, this population of T cells attacks multiple tumor targets and acts to activate the patient's immune system to produce broad spectrum anti-tumor activity. Because Marker does not genetically engineer its T cells, when compared to current engineered CAR-T and TCR-based approaches, its products (i) are significantly less expensive and easier to manufacture, (ii) appear to be markedly less toxic, and (iii) are associated with meaningful clinical benefit. As a result, Marker believes its portfolio of T cell therapies has a compelling therapeutic product profile, as compared to current gene-modified CAR-T and TCR-based therapies.
Marker is also advancing a number of innovative peptide- and gene-based immuno-therapeutics for the treatment of metastatic solid tumors, including the Folate Receptor Alpha program (TPIV200) for breast and ovarian cancers and the HER2/neu program (TPIV100/110) for breast cancer, currently in Phase II clinical trials. In parallel, we are developing a proprietary DNA expression technology named PolyStart™ that can enhance the ability of the immune system to recognize and destroy diseased cells.
For additional information, please call toll free at (904) 862-6490 or visit: markertherapeutics.com
To receive future press releases via email, please visit: https://markertherapeutics.com/email-alerts/
Forward-Looking Statement Disclaimer
This release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Statements in this news release concerning the Company's expectations, plans, business outlook or future performance, and any other statements concerning assumptions made or expectations as to any future events, conditions, performance or other matters, are "forward-looking statements". Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: our research and development activities relating to our non-engineered multi-tumor antigen specific T cell therapies; our TPIV200 and TPIV100/110 programs and our PolyStart™ program; the effectiveness of these programs or the possible range of application and potential curative effects and safety in the treatment of diseases; and, the timing and success of our clinical trials, as well as multi-tumor antigen specific T cell clinical trials conducted by our collaborators. Forward-looking statements are by their nature subject to risks, uncertainties and other factors which could cause actual results to differ materially from those stated in such statements. Such risks, uncertainties and factors include, but are not limited to the risks set forth in the Company's most recent Form 10-K, 10-Q and other SEC filings which are available through EDGAR at www.sec.gov. The Company assumes no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.
SOURCE Marker Therapeutics, Inc.